Clinical Trial

Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (Axitinib Implant) in Subjects With Neovascular Age-Related Macular Degeneration

Active, Not Recruiting Phase 3
View on ClinicalTrials.gov →
Record status
This record was last updated April 18, 2025 (before its estimated April 29, 2026 completion). Its status may not reflect the trial's current state.
Summary
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (axitinib implant) in Subjects with Neovascular Age-Related Macular Degeneration
Protocol Amendment History 4 amendments
This ClinicalTrials.gov record has been amended 4 times since 2024-01-24; most recent amendment 2025-04-15.
Status change: Recruiting → Active, Not Recruiting 2025-02-03
Status change: Not Yet Recruiting → Recruiting 2024-02-12
Trial Details
NCT Number NCT06223958
Lead Sponsor Ocular Therapeutix, Inc.
Collaborators: Fortrea, Duke University
Conditions Neovascular Age-Related Macular Degeneration
Enrollment 344 participants
Start Date 2024-01-29
Primary Completion 2026-04-29 (estimated)
Study Completion 2027-09-27 (estimated)
Updated on ClinicalTrials.gov 2025-04-18